Loading stock data…
Precigen, Inc. (PGEN)
$5.92+0.06 (+1.02%)
After Hours$5.99+0.07 (+1.18%)· Last close Jun 29
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precigen, Inc. in the Healthcare sector is trading at $5.92 with a market capitalization of $1.4B. Wall Street consensus targets $12.45 (2 analysts), implying a +110.3% move over the next 12 months. The stock is currently near its 52-week high of $6.04, remaining 45.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +110.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $23.25M↑ | $4.57M↑ | $2.92M↑ | $856,000↓ | $1.34M |
| Gross Profit | $20.69M↑ | $2.97M↑ | $1.89M↑ | -$236,000↓ | $241,000 |
| Operating Income | -$5.99M↑ | -$21.67M↑ | -$34.48M↓ | -$27.86M↓ | -$22.60M |
| Net Income | -$7.93M↑ | -$23.50M↑ | -$146.34M↓ | -$26.64M↑ | -$54.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1010.22%
Volume
Today's trading volume
6.17M
Recent News
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason
Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time. Precigen rallied for a second day on Monday, surging 11.62 percent to end at $5.38 apiece, as investors loaded portfolios ahead of the end of the second quarter, with optimism for the period boosted by the orphan drug exclusivity of its therapy […]
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
Precigen Inc. (NASDAQ:PGEN) is one of the penny stocks with explosive growth potential. On June 15, Precigen secured FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine treating adult recurrent respiratory papillomatosis/RRP. This regulatory designation prevents the FDA from approving similar treatments for 7 years, extending the drug’s market exclusivity and protecting its revenue potential […]
H.C. Wainwright Remains a Buy on Precigen (PGEN)
Precigen, Inc. (NASDAQ:PGEN) is one of the Best Penny Stocks That Could Skyrocket in 2026. On June 2, H.C. Wainwright reiterated a Buy rating on Precigen, Inc. (NASDAQ:PGEN) with a price target of $14. The reiterated bullish sentiment comes after the company presented data for PAPZIMEOS at a major oncology conference on May 30. PAPZIMEOS […]
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate
Event backdrop and recent share performance Precigen (PGEN) has seen its stock fluctuate recently, with a decline of 1.8% in the latest session followed by a gain of 24.3% over the past week, drawing fresh attention from investors. Over the past month the stock is up 0.7%. The past 3 months show a 26.8% gain, and the past year reflects a 192.8% total return, highlighting meaningful recent volatility. See our latest analysis for Precigen. The recent 7 day share price return of 24.3% has come...
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Focused on gene and cell therapies, this biotech innovator reported a notable insider sale amid a year of exceptional share price gains.